Economic burden in non-Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross-sectional study.
cancer survivors
explanatory factors
health care cost
health care resource use
non-Hodgkin lymphoma
rituximab
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
revised:
19
08
2021
received:
08
06
2021
accepted:
24
08
2021
pubmed:
5
10
2021
medline:
11
3
2022
entrez:
4
10
2021
Statut:
ppublish
Résumé
No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors. Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways.
Sections du résumé
BACKGROUND
No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors.
METHODS
Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.
RESULTS
In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.
CONCLUSIONS
The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
519-528Subventions
Organisme : Agence Nationale de Sécurité du Médicament et des Produits de Santé
ID : AAP-2012-20
Organisme : Ligue Contre le Cancer
Informations de copyright
© 2021 American Cancer Society.
Références
French National Cancer Institute Accessed May 19, 2021. https://en.e-cancer.fr/
Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96:1136-1143. doi:10.3324/haematol.2010.038109
Younes A, Ansell S, Fowler N, et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14:335-346. doi:10.1038/nrclinonc.2016.205
Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076-1088. doi:10.1016/S1470-2045(17)30444-8
Boulat T, Ghosn W, Morgand C, Falissard L, Roussel S, Rey G. Principales évolutions de la mortalité par cause sur la période 2000-2016 en France métropolitaine. Bull Epidémiol Hebd. 2019;29-30:576-584.
Améliorer la qualité du système de santé et maîtriser les dépenses. L'Assurance Maladie. Accessed May 19, 2021. https://www.ameli.fr/sites/default/files/rapport-charges-et-produits-2020.pdf
Burudpakdee C, Lin HM, Wang W, et al. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. J Med Econ. 2016;19:965-972. doi:10.1080/13696998.2016.1187622
Maziarz RT, Hao Y, Guerin A, et al. Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59:1133-1142. doi:10.1080/10428194.2017.1375100
Albarmawi H, Nagarajan M, Sun K, et al. Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data. Leuk Lymphoma. 2020;61:75-83. doi:10.1080/10428194.2019.1648804
Foster T, Miller JD, Boye ME, Russell MW. Economic burden of follicular non-Hodgkin's lymphoma. Pharmacoeconomics. 2009;27:657-679. doi:10.2165/11314820-000000000-00000
Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019;19:645-661. doi:10.1080/14737167.2019.1680288
Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymphoma. 2006;47:1535-1544. doi:10.1080/10428190600573325
Danese MD, Reyes CM, Gleeson ML, Halperin M, Skettino SL, Mikhael J. Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real-world data. Med Care. 2016;54:343-349. doi:10.1097/MLR.0000000000000486
Griffiths RI, Gleeson ML, Mikhael J, Danese MD. Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare. J Cancer Epidemiol. 2012;2012:978391. doi:10.1155/2012/978391
Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2011;52:2117-2123. doi:10.3109/10428194.2011.592623
Morrison VA, Bell JA, Hamilton L, et al. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA. Future Oncol. 2018;14:2627-2642. doi:10.2217/fon-2018-0267
Muneishi M, Nakamura A, Tachibana K, et al. Retrospective analysis of first-line treatment for follicular lymphoma based on outcomes and medical economics. Int J Clin Oncol. 2018;23:375-381. doi:10.1007/s10147-017-1202-2
Monga N, Nastoupil L, Garside J, et al. Burden of illness of follicular lymphoma and marginal zone lymphoma. Ann Hematol. 2019;98:175-183. doi:10.1007/s00277-018-3501-8
Yang X, Laliberté F, Germain G, et al. Real-world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B-cell lymphoma in the U.S. Oncologist. 2021;26:e817-e826. doi:10.1002/onco.13721
Mounier N, Anthony S, Busson R, et al. Long-term fatigue in survivors of non-Hodgkin lymphoma: the Lymphoma Study Association SIMONAL cross-sectional study. Cancer. 2019;125:2291-2299. doi:10.1002/cncr.32040
ATC classification system: structure and principles. WHO Collaborating Centre for Drug Statistics Methodology. Accessed May 19, 2021. https://www.whocc.no/atc/structure_and_principles/
Choices in Methods for Economic Evaluation. French National Authority for Health. Accessed May 19, 2021. https://www.has-sante.fr/jcms/r_1499251/en/choices-in-methods-for-economic-evaluation
Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001;20:461-494. doi:10.1016/s0167-6296(01)00086-8
Yvonne M, Bishop Y, Fienberg S, Holland P. Discrete Multivariate Analysis Theory and Practice. Springer; 2007.
You CH, Kang S, Kwon YD. The economic burden of breast cancer survivors in Korea: a descriptive study using a 26-month micro-costing cohort approach. Asian Pac J Cancer Prev. 2019;20:2131-2137. doi:10.31557/APJCP.2019.20.7.2131
Zhang X, Liu S, Liu Y, et al. Economic burden for lung cancer survivors in urban China. Int J Environ Res Public Health. 2017;14:308. doi:10.3390/ijerph14030308
Barrows CE, Belle JM, Fleishman A, Lubitz CC, James BC. Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors. Surgery. 2020;167:378-384. doi:10.1016/j.surg.2019.09.010
Massa ST, Osazuwa-Peters N, Adjei Boakye E, Walker RJ, Ward GM. Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors. JAMA Otolaryngol Head Neck Surg. 2019;145:239-249. doi:10.1001/jamaoto.2018.3982